Rangeley Capital’s Inhibrx INBX Stock Holding History

Rangeley Capital’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-17,810	Closed	-$249K	–	91
2025 Q1	$249K	Sell	17,810 -31,591	-64%	-$429K	0.27%	48
2024 Q4	$761K	Buy	+49,401	New	+$752K	0.68%	39

Other funds holding INBX

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Rangeley Capital's INBX Position: Q2 2025 in Review

Rangeley Capital sold out of Inhibrx (INBX) in Q2 2025, closing a stake of 17,810 shares — an estimated $249K sold.

Rangeley Capital first reported a position in INBX in Q4 2024 and held it in 2 quarters. The position peaked at $761K in Q4 2024. 88 funds tracked by Wall St. Rank hold INBX as of Q2 2025.

Rangeley Capital reported no remaining Inhibrx position as of Q2 2025 after selling out during the quarter.
Rangeley Capital sold 17,810 Inhibrx shares in Q2 2025, an estimated $249K.
Rangeley Capital first reported a position in Inhibrx in Q4 2024 and held it in 2 quarters.
Rangeley Capital's Inhibrx position peaked at $761K in Q4 2024.
88 funds tracked by Wall St. Rank held Inhibrx as of Q2 2025.

Based on Rangeley Capital's 13F filing for Q2 2025, filed 14 Aug 2025.